146 related articles for article (PubMed ID: 28029415)
1. Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis.
Kawalec P; Malinowski KP
Health Policy; 2016 Nov; 120(11):1240-1248. PubMed ID: 28029415
[TBL] [Abstract][Full Text] [Related]
2. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.
Kawalec P; Malinowski KP; Trąbka W
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):197-205. PubMed ID: 28952400
[TBL] [Abstract][Full Text] [Related]
3. Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014.
Malinowski KP; Kawalec P; Trąbka W
Health Policy; 2016 Nov; 120(11):1249-1255. PubMed ID: 27884491
[TBL] [Abstract][Full Text] [Related]
4. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes.
Wilk N; Wierzbicka N; Skrzekowska-Baran I; Moćko P; Tomassy J; Kloc K
Public Health; 2017 Apr; 145():51-58. PubMed ID: 28359391
[TBL] [Abstract][Full Text] [Related]
5. Drug Policy in Poland.
Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
[TBL] [Abstract][Full Text] [Related]
6. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
Lipska I; McAuslane N; Leufkens H; Hövels A
Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
[TBL] [Abstract][Full Text] [Related]
7. AOTMiT reimbursement recommendations compared to other HTA agencies.
Mela A; Lis D; Rdzanek E; Jaroszyński J; Furtak-Niczyporuk M; Drop B; Blicharski T; Niewada M
Eur J Health Econ; 2024 Jan; ():. PubMed ID: 38261131
[TBL] [Abstract][Full Text] [Related]
8. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
[TBL] [Abstract][Full Text] [Related]
9. A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland.
Kolasa K; Schubert S; Manca A; Hermanowski T
Health Policy; 2011 Oct; 102(2-3):145-51. PubMed ID: 21641074
[TBL] [Abstract][Full Text] [Related]
10. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
Neumann D; Jabłecka A
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
[TBL] [Abstract][Full Text] [Related]
11. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
[TBL] [Abstract][Full Text] [Related]
12. The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland.
Bochenek T; Kocot E; Rodzinka M; Godman B; Maciejewska K; Kamal S; Pilc A
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):385-400. PubMed ID: 27882823
[TBL] [Abstract][Full Text] [Related]
13. Health technology assessment of public health programmes in Poland, years 2010 and 2013.
Kolasa K; Turlej A; Hermanowski T
Przegl Epidemiol; 2016; 70(1):77-81, 151-4. PubMed ID: 27344479
[TBL] [Abstract][Full Text] [Related]
14. Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries.
Stawowczyk E; Malinowski KP; Kawalec P; Bobiński R; Siwiec J; Panteli D; Eckhardt H; Simoens S; Agusti A; Dooms M; Pilc A
Front Pharmacol; 2019; 10():1279. PubMed ID: 31827433
[No Abstract] [Full Text] [Related]
15. Chance of reimbursement for ADD-ON therapies in Poland and in the world - review of the reimbursement recommendations.
Borowiack E; Marzec M; Nowotarska A; Jarosz J; Orkisz A; Prząda-Machno P
Przegl Epidemiol; 2018; 72(1):99-109. PubMed ID: 29667385
[TBL] [Abstract][Full Text] [Related]
16. From idealistic rookies to a regional leader: the history of health technology assessment in Poland.
Nizankowski R; Wilk N
Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():156-62. PubMed ID: 19527537
[TBL] [Abstract][Full Text] [Related]
17. Health technology assessment in Poland and Scotland: comparison of process and decisions.
Kolasa K; Wasiak R
Int J Technol Assess Health Care; 2012 Jan; 28(1):70-6. PubMed ID: 22617739
[TBL] [Abstract][Full Text] [Related]
18. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
Kawalec P; Sagan A; Pilc A
Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
[TBL] [Abstract][Full Text] [Related]
19. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
McCormick JI; Berescu LD; Tadros N
Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
[TBL] [Abstract][Full Text] [Related]
20. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
Maynou L; Cairns J
Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
